Merck reorganizes ahead of looming Keytruda patent cliff — Facing the anticipated loss of U.S. exclusivity for its blockbuster cancer drug Keytruda, Merck & Co. is splitting its human health business into two focused units: a standalone oncology division and a separate specialty, pharma & infectious diseases unit. The oncology arm will manage Keytruda and other cancer therapies, while non-cancer products like Winrevair and Januvia, along with vaccines, move to the other unit. The shakeup is aimed at sharpening execution and positioning the company for long-term growth beyond Keytruda’s peak sales years. Leadership changes accompany the restructure as Merck doubles down on its post-Keytruda strategy.
Click here to read the entire article.
